Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Yasuhiko Fukuta"'
Autor:
Yuna Sugimoto, Kayo Yamamura, Tomoyo Takayama, Yasuhiko Fukuta, Kazuo Aoki, Katsunaka Mikami, Akemi Tomoda
Publikováno v:
BMC Psychiatry, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background The purpose of this study was to evaluate the post-marketing safety and effectiveness of aripiprazole in treating irritability in pediatric patients (6–17 years) with autism spectrum disorder (ASD) in actual clinical sites of Ja
Externí odkaz:
https://doaj.org/article/587cb327d20c431997f7b6e154fd5329
Publikováno v:
International Journal of Neuroscience. 132:237-247
The aim of this study was to evaluate the safety and effectiveness of rotigotine under daily clinical practice in Parkinson's disease patients.The study was a prospective, non-interventional, observational study targeting patients who were treated wi
Autor:
Mitsuru Okada, Takahiro Hirano, Shuji Terai, Masayuki Kurosaki, Isao Sakaida, Yasuhiko Fukuta
Publikováno v:
Journal of Gastroenterology
BackgroundThis large-scale post-marketing surveillance study (START study) evaluated the effectiveness and safety of tolvaptan in Japanese liver cirrhosis patients with hepatic edema in real-world clinical settings. Here, we present the final analysi
Autor:
Akemi Tomoda, Katsunaka Mikami, Kazuo Aoki, Tomoyo Takayama, Yasuhiko Fukuta, Kayo Yamamura, Yuna Sugimoto
Publikováno v:
BMC Psychiatry
BMC Psychiatry, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Psychiatry, Vol 21, Iss 1, Pp 1-12 (2021)
Background The purpose of this study was to evaluate the post-marketing safety and effectiveness of aripiprazole in treating irritability in pediatric patients (6–17 years) with autism spectrum disorder (ASD) in actual clinical sites of Japan. Meth
Autor:
Shuji Terai, Mitsuru Okada, Kosuke Bando, Masayuki Kurosaki, Yasuhiko Fukuta, Moriyoshi Yasuda, Isao Sakaida
Publikováno v:
Hepatology Research. 47:1137-1146
Aim Loop diuretics and spironolactone are used in patients with hepatic edema, but they are sometimes associated with insufficient responses as well as adverse events. Tolvaptan, a vasopressin type 2 receptor antagonist, was approved for hepatic edem
Autor:
Koichiro Kinugawa, Kosuke Bando, Yasuhiko Fukuta, Takayuki Inomata, Toshiyuki Shimakawa, Naoki Sato, Moriyoshi Yasuda
Publikováno v:
International Heart Journal. 58:30-35
The vasopressin receptor 2 (V2) receptor antagonist tolvaptan is an aquaretic agent that has been approved for heart failure patients with volume overload in Japan. In this study (SMILE study), we investigated patient characteristics and effectivenes
Autor:
Koichiro Kinugawa, Moriyoshi Yasuda, Naoki Sato, Takayuki Inomata, Toshiyuki Shimakawa, Yasuhiko Fukuta
Publikováno v:
International heart journal. 60(5)
Tolvaptan, a vasopressin V2 receptor antagonist, is approved in Japan for the treatment of fluid retention in patients with heart failure (HF), and in the United States for hyponatremia. The efficacy and safety of tolvaptan in patients with HF with r
Autor:
Yasuhiko Fukuta, Naoki Sato, Takayuki Inomata, Moriyoshi Yasuda, Koichiro Kinugawa, Toshiyuki Shimakawa
Publikováno v:
Circulation journal : official journal of the Japanese Circulation Society. 83(7)
Background In Japan, tolvaptan is indicated for patients with heart failure and volume overload who have inadequate response to other diuretics. In contrast to the USA and Europe, tolvaptan can be used in Japan in patients with normal sodium levels.M
Publikováno v:
Current medical research and opinion. 34(12)
Augmentation therapy is an option for patients with major depressive disorder who do respond sufficiently to adequate dosages of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, but little is known about applic
Autor:
Isao, Sakaida, Shuji, Terai, Masayuki, Kurosaki, Moriyoshi, Yasuda, Mitsuru, Okada, Kosuke, Bando, Yasuhiko, Fukuta
Publikováno v:
Hepatology research : the official journal of the Japan Society of Hepatology. 47(11)
Loop diuretics and spironolactone are used in patients with hepatic edema, but they are sometimes associated with insufficient responses as well as adverse events. Tolvaptan, a vasopressin type 2 receptor antagonist, was approved for hepatic edema in